Manufacturer
JANSSEN
Contents
Decitabine
Indication
Myelodysplastic syndromes (MDS) including previously treated & untreated, de novo & secondary MDS of all FAB subtypes, & Int-1, Int-2 & high risk IPSS groups. Adults ≥65 yr w/ newly diagnosed de novo or secondary AML who are not candidates for standard induction chemotherapy
Instruction
DACOGEN is administered by intravenous infusion. A central venous catheter is not required. For instructions on reconstitution and dilution of the medicinal product before administration, see Instructions for Use and Handling and Disposal under Cautions for Usage.
Drug interaction
Other agents activated by sequential phosphorylation via intracellular phosphokinase activities &/or metabolized by enzymes implicated in decitabine inactivation.
Malaysia
